Clinical Trials
25 trialsA Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
Resimmune®
Virogen Biotechnology Inc.
PEM-PRO
IRCCS San Raffaele
A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation
M.D. Anderson Cancer Center
T-ALL-2024
Institute of Hematology & Blood Diseases Hospital, China
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
M.D. Anderson Cancer Center
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
M.D. Anderson Cancer Center
Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy
Rutgers, The State University of New Jersey
Immunotherapy Before and After Surgery
ImmunityBio, Inc.
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.
ImmunityBio, Inc.
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
M.D. Anderson Cancer Center
ADJUNCT
MedSIR
BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT
Institute of Hematology & Blood Diseases Hospital, China
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
Vanderbilt-Ingram Cancer Center
Perioperative Immunotherapy for NSCLC (ECTOP-1030)
Fudan University
Copaíba-based Mouthwash in Oral Mucotitis Prevention and Treatment in Oral Cancer Patients During Radioteraphy
Instituto Nacional de Cancer, Brazil
HARMONY
Hoosier Cancer Research Network
ECLAT
Memorial Sloan Kettering Cancer Center
MONAMI
Assistance Publique - Hôpitaux de Paris
Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals, Inc
exBOND
CG Oncology, Inc.
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Dana-Farber Cancer Institute
INDIGO
Gustave Roussy, Cancer Campus, Grand Paris
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
OZM-034
University Health Network, Toronto